NovaBay Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, NBY, NovaBay Pharmaceuticals Inc, priceseries

NovaBay Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.28
Close
0.27
High
0.29
Low
0.27
Previous Close
0.29
Daily Price Gain
-0.02
YTD High
0.43
YTD High Date
Jan 4, 2022
YTD Low
0.27
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.14
YTD Gain
-33.75%
52 Week High
1.19
52 Week High Date
Mar 19, 2021
52 Week Low
0.27
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-0.58
52 Week Gain
-68.72%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
2.80
Jun 28. 2017
3.21
7 Trading Days
14.68%
Link
LONG
Mar 14. 2018
3.25
Mar 27. 2018
3.46
9 Trading Days
6.45%
Link
LONG
Jun 8. 2018
2.80
Jun 11. 2018
3.27
1 Trading Days
16.88%
Link
LONG
Jan 15. 2019
1.08
Jan 17. 2019
1.14
2 Trading Days
5.09%
Link
LONG
Jan 23. 2019
1.38
Feb 1. 2019
1.60
7 Trading Days
16.18%
Link
LONG
Jun 10. 2019
3.10
Jun 11. 2019
3.57
1 Trading Days
15.16%
Link
LONG
Jun 22. 2020
0.96
Jun 25. 2020
1.03
3 Trading Days
7.02%
Link
LONG
Feb 3. 2021
0.95
Feb 17. 2021
1.08
9 Trading Days
13.89%
Link
LONG
Feb 18. 2021
1.43
Feb 19. 2021
1.50
1 Trading Days
5.24%
Link
Company Information
Stock Symbol
NBY
Exchange
NYSE MKT
Company URL
http://novabay.com
Company Phone
(510) 899-8800
CEO
Mark M. Sieczkarek
Headquarters
California
Business Address
2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001389545
About

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing products for the eye care. The company's products include Avenova, which is designed to remove foreign materials including microorganisms and debris on and around the lid and eyelid margins that may be due to Blepharitis, Meibomian Gland Dysfunction and dry eye; NeutroPhase, is a skin and wound cleanser consisting of neutrox; and cellerx, it cleans, calms and soothes skins. NovaBay Pharmaceuticals was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Description

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading